Dear Lori,

Thank-you for giving us the opportunity to comment on the appraisal consultation document for 'Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia [ID650]'.

We would like to comment that Leukaemia CARE is happy with the appraisal committee's preliminary recommendations that:

> "Obinutuzumab, in combination with chlorambucil, is recommended as an option for adults with untreated chronic lymphocytic leukaemia who have comorbidities that make full-dose fludarabine-based therapy unsuitable for them, only if:
>
> - bendamustine-based therapy is not suitable **and**
> - the company provides obinutuzumab with the discount agreed in the patient access scheme."

Kind Regards,

[redacted]

[redacted] [redacted]

(On Behalf of – [redacted] [redacted] Leukaemia CARE)